Drug Product De-TIL-0255
Phase 1Terminated 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-resistant Ovarian Cancer
Conditions
Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer
Trial Timeline
Dec 22, 2021 → May 9, 2023
NCT ID
NCT05107739About Drug Product De-TIL-0255
Drug Product De-TIL-0255 is a phase 1 stage product being developed by Nurix Therapeutics for Platinum-resistant Ovarian Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05107739. Target conditions include Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05107739 | Phase 1 | Terminated |
Competing Products
16 competing products in Platinum-resistant Ovarian Cancer